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In a careful examination of our recent review of
salvage therapies for steroid-refractory acute graft-
versus-host disease (aGVHD) [1], Greinix et al. have
rightfully identified that the discussion of extracorpo-
real photopheresis (ECP) did not include all published
data. Specifically, our review cited the results of a pilot
study conducted by Greinix et al. [2], but did not in-
clude a later report that summarized both the results
of the pilot study and a prospective phase II trial [3].
In their response to our review, Greinix et al. note
that therewere important differences in patient charac-
teristics and therapy between the pilot trial and the
phase II trial that might have contributed to more
encouraging responses. Compared with the pilot trial,
the phase II trial showed higher rates of complete
remission (CR) of aGVHD in patients with gastroin-
testinal involvement (73% vs 25%) and grade IV
disease (60%vs 12%).This does not appear to be a con-
sistent trend, however; the pilot trial showed higher
rates of CR of aGVHD in patients with grade II disease
(100% vs 85%), grade III disease (67% vs 43%), and
liver involvement (67% vs 55%). Moreover, the ability
to draw conclusions about the comparative efficacy of
ECP in grade IV aGVHD across the pilot and phase
II trials is limited by the small number of subjects
(n 5 5 in each trial).
Although limited to small, single-center studies, the
overall experience reported by Greinix et al. and other
published literature suggests that ECP can induce CR
of steroid-refractory aGVHD and can facilitate libera-
tion from glucocorticoids. We agree that prospective,
well-designed studies on refractory aGVHD are needed
to discern the true benefit of salvage therapies.REFERENCES
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Disease of the Liver?
Wewerepleased to read the article byCutler et al. [1]
recently published in BBMT. Veno-occlusive disease of
the liver (VOD) is a serious complication of hematopoi-
etic stem cell transplantation (HSCT), particularly
after busulfan (BU)-based conditioning regimens,
and it could be very important to identify biomarkers
useful to predict its occurrence. We agree with the au-
thors that the pathogenesis of VOD is multifactorial.
In this regard we have noticed that some clinical as-
pects can be commonly observed both in VOD and
HELLP (hemolysis, elevated liver enzymes, and low
platelet number) syndrome. VOD is thought to be ini-
tiated by injury to the area surrounding the central
vein; damage is seen in sinusoidal endothelial cells
(EC) and in hepatocytes in zone 3 of the liver acinus.
Structural damage continues with progressive venular
occlusion, culminating in widespread zonal liver dis-
ruption. Recently, several cases of HELLP syndrome
have been associated with complement disregulation
[2], which is frequently observed in aHUS (atypical
hemolytic uremic syndrome). In aHUS, microvascular
EC injury has been linked to excessive complement
activation via the alternative pathway (AP), in that ap-
proximately 50% of these patients have AP complement
activating missense mutations or functional variants in
genes encoding complement regulatory proteins: factor
H (CFH), factor I (CFI), membrane cofactor protein
(MCP), CFH-related proteins, C4b binding protein,
thrombomodulin, C3, and factor B [3-5].
A pilot study was conducted to identify sequence
variants of CFH and CFI in 7 patients who had under-
gone an allogeneic HSCTwith BU and cyclophospha-
mide (CY) conditioning regimen for acute myeloid
leukemia (AML). Three patients showed classical signs
of VOD according to the Seattle criteria within 35 days
from the transplant. The remaining 4 control patients
did not exhibit clinical signs of VOD. All samples, for
gene sequence evaluation, were obtained before
treatment for AML.
No CFI gene sequence variants were detected in
either VOD or control groups. Two variants of the
CFH gene were detected exclusively in the VOD
group. One was a novel intronic variant, IVS 18-86
T.C, whereas the other, p.E936D, had been previ-
ously associated with aHUS [5].
Our preliminary study might suggest that disregu-
lation of the complement system may represent the
first step of the process. These data could support
the conclusions of Cutler et al. [1], suggesting the
